Abcuro

Abcuro announced $66M in Series D financing on August 18, 2026. Abcuro raised a $66 million Series D led by New Leaf Venture Partners to fund a new potentially registrational study of ulviprubart in inclusion body myositis.

Round details

The financing includes backing from New Leaf Venture Partners, Rock Springs Capital, abrdn Inc., Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management. The company did not publish a valuation with the announcement.

• Round: Series D
• Capital announced: $66M

How the company plans to use the capital

Abcuro said proceeds will support a new potentially registrational clinical study of ulviprubart in patients with less severe inclusion body myositis, which it expects to start in the fourth quarter of 2026. Assuming positive results, the company said it plans to file a biologics license application.

Why this matters for GTM teams

Existing investor New Leaf Venture Partners led the round and Rock Springs Capital joined as a new investor, ahead of a new potentially registrational study of ulviprubart.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Abcuro Series D announcement.